RHB Retail Research
Trading Stocks - Duopharma Biotech
Duopharma Biotech may climb higher after forming a white candle and hitting its new 52-week high. With the 21-day SMA line edging upwards, this implies a positive outlook. A positive bias may emerge above the MYR1.58 level, with an exit set below the MYR1.51 threshold. Towards the upside, the immediate resistance is at the MYR1.70 mark. This is followed by the MYR1.80 level.
Source: RHB Securities Research - 10 Jan 2020
More articles on RHB Retail Research
Duopharma Biotech - Lacking Near-Term Re-Rating Catalysts; D/G NEUTRAL
Created by rhboskres | Aug 26, 2024
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
2
3
save malaysia!
Visa-free travel to China extended for Malaysians to 30 days
4
Good Articles to Share
5
Good Articles to Share
Four convicted in Spain over homophobic murder that sparked nationwode protests
6
Good Articles to Share
7
Good Articles to Share
What’s behind the slew of restaurant bankruptcies in 2024? Experts unpack the problems
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
MQ Trading Signals
Stock
Time
Signal
Duration
Stock
Time
Signal
Duration
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
